Acrivon Therapeutics, Inc./$ACRV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Ticker

$ACRV
Sector
Health
Primary listing
NASDAQ

Employees

75
Headquarters
Watertown, United States
Website
acrivon.com

ACRV Metrics

BasicAdvanced
$71m
-
-$2.00
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACRV

Sign up or log in to buy
Capital at risk
Market openLow-cap

Upcoming events

No upcoming events
FAQs